Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born

Status Completed

Clinical Trial Summary

The Investigators hope to learn if they can prevent or lessen the symptoms of neonatal abstinence syndrome (NAS) in babies born to narcotic-dependent mothers by using the drug ondansetron in the mothers prior to delivery and their babies after delivery. The study is a randomized, double-blind, placebo-controlled study with one half the mother-baby pairs to receive ondansetron and the other half of the mother-baby pairs to receive placebo. The pregnant narcotic-dependent mothers will receive an intravenous dose of study medication prior to delivery; the neonates, after their birth, will receive the same study medication the mother received every 24 hours for up to 5 days. The Investigators will follow up with the mother-baby pairs for 10 days after study drug has stopped and one last follow up, about 30 days after stopping study drug, to learn if the baby had any symptoms of NAS in that time period.

Clinical Trial Description

All neonates will have a screening 12-lead EKG prior to their first dose of study medication to determine if QTc prolongation is present. A repeat 12-lead EKG will be done after each dose of study medication, approximately 2-5 hours post dose; if a neonate has prolonged QTc the study drug will be stopped. Investigators may obtain up to 9 pharmacokinetic (PK) blood samples from the neonates over 5 days when standard of care blood samples are drawn. These samples will consist of 1 to 2 drops of blood collected on filter paper and sent to Stanford for PK analysis. The modified Finnegan scoring system will be used to evaluate neonates for symptoms of NAS at each site and it is considered standard-of-care for babies at risk of NAS. Morphine will be the first treatment choice before other treatment medication choices (opioid or non-opioid) for NAS symptoms. Each site involved has established guidelines for starting, advancing and weaning treatment for NAS. Any medication used to treat NAS will be recorded. Interim analysis: will be performed after the first 20 pregnant women and their neonates have been enrolled and dosed with study drug. (Interim Analysis was done on first 21 mother/baby pairs in May 2016). To protect the confidentiality of the patients (study subjects), the lead site, Stanford University, received a Certificate of Confidentiality from the NIH. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01965704
Study type	Interventional
Source	Stanford University
Contact
Status	Completed
Phase	Phase 2
Start date	September 9, 2014
Completion date	September 16, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03890562` - Assessing the Effects of Auricular Acupressure on Newborns With NAS	N/A
Completed	`NCT01958476` - Improving Outcomes in Neonatal Abstinence Syndrome	Phase 3
Active, not recruiting	`NCT01734551` - NAS Treatment - Opiate Versus Non-Opiate	Phase 4
Completed	`NCT00496951` - Vagal Tone and Neonatal Abstinence Syndrome	N/A
Completed	`NCT02851303` - Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome	Phase 4
Recruiting	`NCT05226624` - The Alberta Neonatal Abstinence Syndrome Mother-Baby Care ImprovEmeNT Program	N/A
Completed	`NCT03670160` - Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome	Phase 2
Not yet recruiting	`NCT04611659` - Averting NAS Among Opioid-Using Young Women Receiving MAT Using Buprenorphine	N/A
Completed	`NCT01452789` - Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome	Phase 3
Completed	`NCT04588519` - tAN to Mitigate Withdrawal Behaviors in Neonates	N/A
Completed	`NCT02797990` - Conflict Between Maternal Autonomy and Child Health in Substance-use	N/A
Completed	`NCT02801331` - Efficacy and Outcomes of a Non-Pharmacological Intervention for Neonatal Abstinence Syndrome	N/A
Terminated	`NCT03246243` - Quantitative Assessment of Sucking for Early Diagnosis of Brain Injury in Infants at High Risk
Completed	`NCT03567603` - Sound Processing Changes in Babies With Opioid Exposure
Recruiting	`NCT06303986` - Study to Collect Data for Neonatal Abstinence Syndrome (NAS) and Evaluate the Automated Data Collection Process
Active, not recruiting	`NCT03725332` - The PATH Home Trial: A Comparative Effectiveness Study of Peripartum Opioid Use Disorder in Rural Kentucky	N/A
Recruiting	`NCT04983563` - Actigraphy and Neonatal Abstinence Syndrome of Hospitalized Newborn in Intensive Care Units	N/A
Completed	`NCT04298853` - Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome	Phase 4
Completed	`NCT02182973` - Donor Human Milk in Neonatal Abstinence Syndrome
Completed	`NCT02810782` - How to Treat Opiate Withdrawal in Neonates	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women — AIM2NAS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms